Recent advances on smart glycoconjugate vaccines in infections and cancer
Anderluh, Marko (Univerza V Ljubljani)
Berti, Francesco (GlaxoSmithKline (Itàlia))
Bzducha-Wróbel, Anna (Warsaw University of Life Sciences-SGGW, Warszawa, Poland)
Chiodo, Fabrizio (Vrije Universiteit Amsterdam, The Netherlands)
Colombo, Cinzia (University of Milan, Italy)
Compostella, Federica (University of Milan, Italy)
Durlik, Katarzyna (Jan Kochanowski University, Kielce, Poland)
Ferhati, Xhenti (Università degli Studi di Firenze)
Holmdahl, Rikard (Karolinska Institute, Stockholm, Sweden)
Jovanovic, Dragana (University of Belgrade, Serbia)
Kaca, Wieslaw (Jan Kochanowski University, Kielce, Poland)
Lay, Luigi (University of Milan, Italy)
Marinovic-Cincovic, Milena (University of Belgrade, Serbia)
Marradi, Marco (Università degli Studi di Firenze)
Ozil, Musa (Recep Tayyip Erdogan University, Rize, Turkey)
Polito, Laura (National Research Council, CNR-SCITEC, Milan, Italy)
Reina, Jose Juan (Universidad de Malaga-IBIMA)
Reis, Celso A. (University of Porto, Portugal)
Sackstein, Robert (Florida International University, Miami, USA)
Silipo, Alba (Complesso Universitario Monte Sant'Angelo, Napoli, Italy)
Švajger, Urban (Blood Transfusion Center of Slovenia, Ljubljana, Slovenia)
Vaněk, Ondřej (Charles University, Prague, Czech Republic)
Yamamoto, Fumiichiro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Richichi, Barbara (Università degli Studi di Firenze)
van Vliet, Sandra J. (Vrije Universiteit Amsterdam, The Netherlands)

Date:	2022
Abstract:	Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as "tumor-associated carbohydrate antigens". Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Cancer ; Glycosylation ; Immune system ; Infection ; Vaccination
Published in:	FEBS Journal, Vol. 289 Núm. 14 (july 2022) , p. 4251-4303, ISSN 1742-4658

DOI: 10.1111/febs.15909
PMID: 33934527

53 p, 9.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles